Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Other EventsItem 8.01. Other events
Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Other Events
As previously reported on its Form 8-K dated September 26, 2016, Arbutus Biopharma Corporation (the “Corporation”) received notice from the Nasdaq Stock Market on September 26, 2016 that because the Corporation’s audit committee consisted of only two members after the resignation of Mr. Frank Karbe from the audit committee of the board of directors of the corporation, the Corporation was no longer in compliance with Nasdaq’s audit committee requirements set forth in Nasdaq Listing Rule 5605(c)(2) (the “Rule”).
to Nasdaq Listing Rule 5605(c)(4), the Corporation was entitled to a cure period to regain compliance, which cure period would expire upon the earlier of the Corporation’s next annual shareholders’ meeting or September 22, 2017.
On March 24, 2017, the Corporation received notification from the Nasdaq Stock Market that, based on the information detailed in the Corporation’s Form 8-K filed on March 24, 2016 regarding the appointment of Daniel Burgess to the Corporation’s board of directors and audit committee, it has determined that the Corporation has regained compliance with the Rule and this matter is now closed.
About Arbutus Biopharma Corporation (NASDAQ:ABUS)
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists. Arbutus Biopharma Corporation (NASDAQ:ABUS) Recent Trading Information
Arbutus Biopharma Corporation (NASDAQ:ABUS) closed its last trading session up +0.05 at 3.25 with 117,823 shares trading hands.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists. Arbutus Biopharma Corporation (NASDAQ:ABUS) Recent Trading Information
Arbutus Biopharma Corporation (NASDAQ:ABUS) closed its last trading session up +0.05 at 3.25 with 117,823 shares trading hands.
